JPMorgan Chase & Co. Boosts Solid Biosciences (NASDAQ:SLDB) Price Target to $12.00

Solid Biosciences (NASDAQ:SLDB) had its price target hoisted by equities research analysts at JPMorgan Chase & Co. from $11.00 to $12.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 67.36% from the company’s current price.

SLDB has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Solid Biosciences in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Chardan Capital restated a “buy” rating and set a $15.00 target price on shares of Solid Biosciences in a research report on Friday, March 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of Solid Biosciences in a research report on Friday, March 20th. Finally, Guggenheim assumed coverage on shares of Solid Biosciences in a research report on Friday, March 20th. They issued a “buy” rating and a $26.00 price objective for the company. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.09.

Solid Biosciences Stock Up 7.3%

Shares of NASDAQ:SLDB traded up $0.49 during midday trading on Wednesday, reaching $7.17. The company’s stock had a trading volume of 177,305 shares, compared to its average volume of 1,352,834. The firm has a market capitalization of $558.61 million, a PE ratio of -3.57 and a beta of 2.65. The stock has a fifty day moving average of $6.50 and a 200 day moving average of $5.81. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $8.72.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. Sell-side analysts anticipate that Solid Biosciences will post -2.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Alexander Cumbo sold 80,258 shares of Solid Biosciences stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $516,861.52. Following the transaction, the chief executive officer directly owned 270,931 shares in the company, valued at $1,744,795.64. The trade was a 22.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gabriel Brooks sold 28,335 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $6.44, for a total transaction of $182,477.40. Following the completion of the sale, the insider owned 96,708 shares of the company’s stock, valued at approximately $622,799.52. This trade represents a 22.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 597,672 shares of company stock valued at $3,816,546 in the last three months. Insiders own 13.63% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. AQR Capital Management LLC bought a new position in shares of Solid Biosciences in the first quarter valued at approximately $418,000. Goldman Sachs Group Inc. boosted its holdings in Solid Biosciences by 32.2% during the first quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company’s stock valued at $667,000 after purchasing an additional 43,910 shares in the last quarter. Woodline Partners LP acquired a new position in Solid Biosciences during the 1st quarter worth about $2,338,000. Geode Capital Management LLC raised its holdings in Solid Biosciences by 184.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock worth $7,356,000 after purchasing an additional 979,294 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in Solid Biosciences by 233.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after acquiring an additional 10,585 shares during the period. 81.46% of the stock is owned by institutional investors and hedge funds.

Solid Biosciences News Summary

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: HC Wainwright raised its quarterly and full‑year EPS forecasts for 2026 (Q1–Q4) and lifted FY2026 loss estimates to (‑$1.43) from (‑$2.12), while keeping a “Buy” rating and a $20 price target — a more constructive analyst outlook helped support the rally. Article Title
• Positive Sentiment: HC Wainwright’s model also projects eventual profitability in later years (FY2029: $0.89 EPS; FY2030: $1.81 EPS), signaling a pathway to long‑term upside if the company executes on clinical and commercial milestones. Article Title
• Neutral Sentiment: The market consensus still shows significant near‑term losses (current consensus FY running ~‑$2.84 EPS). HC Wainwright’s improved forecasts are meaningful relative to prior estimates but do not remove near‑term loss risk.
• Neutral Sentiment: Multiple short‑interest updates published for March show “0 shares” and NaN changes — data appears inconsistent or misreported, so there’s no clear signal of increased short pressure from those reports.
• Negative Sentiment: Despite analyst optimism, Solid remains unprofitable through HC Wainwright’s 2026–2027 forecasts (multiple quarters of negative EPS). Execution, clinical progress, and cash runway remain primary downside risks for the stock if milestones slip.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.